Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
The British Journal of Surgery|February 22, 2018
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancerR F D van la Parra, A B Tadros, C M Checka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinomaSusan K Lutgendorf, Donald M Lamkin, Nicholas B Jennings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group studyPaul A DiSilvestro, Shamshad Ali, Peter S Craighead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patientsSusan K Lutgendorf, Aliza Z Weinrib, Frank Penedo, et al.
NAR Genomics and Bioinformatics|June 30, 2025
Novel treatment-specific causal biomarkers for colorectal cancer by omics integrationAkram Yazdani, Azam Yazdani, Raul Mendez-Giraldez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentS Dawood, S D Merajver, P Viens, et al.
Cancer|May 1, 2021
Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancerArlene E Garcia-Soto, Nathalie D McKenzie, Margaret E Whicker, et al.
Gynecologic Oncology|October 27, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG studyRoisin E O'Cearbhaill, Wei Deng, Lee-May Chen, et al.
Annals of Surgical Oncology|December 18, 2018
OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer PatientsS E Tevis, R Bassett, I Bedrosian, et al.
Brain, Behavior, and Immunity|August 14, 2012
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disabilityAndrew Schrepf, Lauren Clevenger, Desire Christensen, et al.
Pageof 9